ClinicalTrials.gg
Status unknownNCT05355207Updated Apr 12, 2023

Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis

A Phase 1 interventional study of TRL1068 in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Trellis Bioscience LLC. Status unknown. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by Trellis Bioscience LLC · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

TRL1068 is expected to eliminate the pathogen-protecting biofilm in Chronic Rhinosinusitis, thus making these bacteria substantially more susceptible to established antibiotic treatment regimens. This initial study is to assess overall safety and pharmacokinetics (PK) of TRL1068. The goal of the development program is to demonstrate effectiveness of TRL1068 in difficult to treat bacterial infections such as in CRS.

Read the detailed description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and decreased quality of life. Defects in the epithelial cell barrier, increased exposure to pathogenic and colonized bacteria, and dysregulation of the host immune system are all thought to play prominent roles in disease pathogenesis. Colonization with S. aureus or P. aureus are associated with recalcitrant disease and biofilm formation, making eradication difficult.

Distribution of topical solutions in the unoperated sinuses has been observed to be less than 2% of the total irrigation volume, with almost no penetration in the frontal and sphenoid sinuses. For those patients with mucosal edema from infection and chronic inflammation, distribution is probably significantly less when applied topically. Intravenously administered TRL1068 is expected to achieve effective anti-biofilm levels throughout the sinonasal space for several weeks. TRL1068 is a monoclonal human antibody that rapidly eliminates biofilm at very low concentrations, thus making the targeted bacterial pathogens substantially more sensitive to standard of care antibiotic treatment regimen and greatly accelerating clinical improvement and potential for bacterial eradication.

02

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps

Keywords

  • biofilm
  • antibiotic-resistant infections
03

In context

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

This study's planned enrollment of 12 is below the median of 60 across 181 interventional studies indexed under Nasal Polyps.

Browse Nasal Polyps studies →

Lead sponsor

Trellis Bioscience LLC is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 85 years, inclusive
  2. Diagnosis of chronic rhinosinusitis with:

    1. Acute exacerbation of CRSwNP with increased sinonasal discharge OR
    2. Acute exacerbation post-functional endoscopic sinus surgery (FESS) with increased sinonasal discharge AND
    3. Sinonasal culture positive for SA or PA without concomitant fungal infection in culture or PCR
  3. Symptoms and culture results justify initiation of topical and/or systemic antibiotic treatment
  4. Willing and able to provide written
  5. Willing to perform and comply with all study procedures including attending clinic visits as scheduled
  6. Men and women of child bearing potential () must be willing to practice a highly effective method of that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods, intrauterine device (IUD), or use of spermicide combined with a barrier method (e.g., condom, diaphragm) for 28 days before receiving the product (IP) and through Day 50.

Exclusion criteria

Exclusion Criteria:

  1. Active , or history of malignancy or chemotherapy within the past 2 years other than history of localized or surgical removal of focal skin cancer, or cervical cancer in situ treated successfully in the past by local treatment (including but not limited to cryotherapy or laser therapy) or by hysterectomy
  2. Any chronic or acute bacterial infection other than acute exacerbation of CRS
  3. Concomitant intrasinal culture or 16S PCR indicative of concomitant fungal infection
  4. Allergic fungal rhinosinusitis, characterized by elevated antifungal IgE and eosinophilic mucus
  5. Receiving or recently received another drug (within 30 days of Day 1, or 5 half-lives of the investigational drug, whichever is longer)
  6. Received a COVID-19 vaccine or booster within 14 days of planned Day 1 or planned COVID-19 vaccination within 14 days after Day 1
  7. Positive serum test for pregnancy, pregnant, or nursing women
  8. History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the subject's ability to comply with the study requirements
  9. Any other comorbidity or condition that, in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with the study requirements
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    TRL1068

    all subjects will receive a single intravenous dose of 15 mg/kg of TRL1068 on Day 1

    Drug: TRL1068

Interventions

  • A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody

06

What researchers measure

Primary outcomes

  1. Incidence of abnormal physical exam findings

    Clinically-significant abnormal physical exam findings will be reviewed

    Time frame: 6 weeks

  2. Incidence of abnormal serum chemistries and hematology

    Clinically-significant abnormal laboratory results will be reviewed

    Time frame: 6 weeks

  3. Incidence of abnormal vital signs (temperature)

    Clinically-significant abnormal temperatures will be reviewed

    Time frame: 6 weeks

  4. Incidence of abnormal vital signs (blood pressure)

    Clinically-significant abnormal blood pressures will be reviewed

    Time frame: 6 weeks

  5. Incidence of abnormal vital signs (heart rate)

    Clinically-significant abnormal heart rates will be reviewed

    Time frame: 6 weeks

  6. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    reported AEs and SAEs will be reviewed

    Time frame: 7 weeks

  7. Characterize the pharmacokinetics (PK) of TRL1068 in serum (Cmax)

    Individual subject TRL1068 Cmax in serum will be determined by ELISA and derived PK parameters will be summarized using descriptive statistics.

    Time frame: 6 weeks

  8. Characterize the pharmacokinetics (PK) of TRL1068 in serum (Cmin)

    Individual subject TRL1068 Cmin in serum will be determined by ELISA and derived PK parameters will be summarized using descriptive statistics.

    Time frame: 6 weeks

  9. Characterize the pharmacokinetics (PK) of TRL1068 in serum (Tmax)

    Individual subject TRL1068 Tmax in serum will be determined by ELISA and derived PK parameters will be summarized using descriptive statistics.

    Time frame: 6 weeks

  10. Characterize the pharmacokinetics (PK) of TRL1068 in serum (AUCLAST)

    Individual subject TRL1068 AUCLAST in serum will be determined by ELISA and derived PK parameters will be summarized using descriptive statistics.

    Time frame: 6 weeks

  11. Characterize the pharmacokinetics (PK) of TRL1068 in serum (AUCINF)

    Individual subject TRL1068 AUCINF in serum will be determined by ELISA and derived PK parameters will be summarized using descriptive statistics.

    Time frame: 6 weeks

  12. Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (Cmax)

    Individual subject TRL1068 Cmax intrasinal will be determined by ELISA and derived PK parameters will be summarized using descriptive statistics.

    Time frame: 6 weeks

  13. Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (Cmin)

    Individual subject TRL1068 Cmin intrasinal will be determined by ELISA and derived PK parameters will be summarized using descriptive statistics.

    Time frame: 6 weeks

  14. Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (Tmax)

    Individual subject TRL1068 Tmax intrasinal will be determined by ELISA and derived PK parameters will be summarized using descriptive statistics.

    Time frame: 6 weeks

  15. Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (AUCLAST)

    Individual subject TRL1068 AUCLAST intrasinal will be determined by ELISA and derived PK parameters will be summarized using descriptive statistics.

    Time frame: 6 weeks

  16. Characterize the pharmacokinetics (PK) of TRL1068 in intrasinal concentrations (AUCINF)

    Individual subject TRL1068 AUCINF intrasinal will be determined by ELISA and derived PK parameters will be summarized using descriptive statistics.

    Time frame: 6 weeks

  17. Characterize the pharmacodynamics (PD) of TRL1068 (time to resolution of bacterial pathogen infection)

    Cultures will be tested for bacterial pathogen presence by bacterial culture and/or PCR assessment. Time to resolution of bacterial pathogen infection is defined as the number of days from start of current acute exacerbation to the day when testing by bacterial culture and/or PCR assessment are reported as negative. Descriptive statistics will be performed including mean, median and confidence interval.

    Time frame: 6 weeks

  18. Characterize the pharmacodynamics (PD) of TRL1068 (time to resolution of signs and symptoms of acute exacerbation)

    Patients will be evaluated for signs and symptoms of acute exacerbation using SNOT-22 scoring. Time to resolution of signs and symptoms of acute exacerbation is defined as the day when the SNOT-22 score is back to pre-acute exacerbation score.

    Time frame: 6 weeks

  19. Assess the immunogenicity of TRL1068 as measured by anti-drug antibodies (ADAs)

    Anti-drug antibodies (ADA), i.e. anti-TRL1068 antibodies in serum will determined by electrochemiluminescence assay

    Time frame: 6 weeks

Secondary outcomes

  1. Assess the incidence of improvement of baseline symptoms of chronic rhinosinusitis (CRS) after intravenous TRL1068

    signs and symptoms will be measured using the SNOT-22

    Time frame: 7 weeks

  2. Assess time to improvement of baseline symptoms of CRS as compared with previous duration of acute exacerbations

    signs and symptoms will be measured using the SNOT-22 and compared with historical data

    Time frame: 7 weeks

Other outcomes

  1. Assess the effects of treatment on the intrasinal microbiome

    intrasinal culture and PCR results will be reviewed

    Time frame: 6 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Estelles A, Woischnig AK, Liu K, Stephenson R, Lomongsod E, Nguyen D, Zhang J, Heidecker M, Yang Y, Simon RJ, Tenorio E, Ellsworth S, Leighton A, Ryser S, Gremmelmaier NK, Kauvar LM. A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2292-301. doi: 10.1128/AAC.02588-15. Print 2016 Apr. PubMed 26833157 ↗
  • Xiong YQ, Estelles A, Li L, Abdelhady W, Gonzales R, Bayer AS, Tenorio E, Leighton A, Ryser S, Kauvar LM. A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections. Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00904-17. doi: 10.1128/AAC.00904-17. Print 2017 Oct. PubMed 28717038 ↗

Individual participant data

Plan to share: Yes — We plan to make the Clinical Protocol and SAP available on Protocols.io (https://www.protocols.io/) before trial recruitment is complete.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Before trial recruitment is complete on Protocols.io (https://www.protocols.io/)

Access criteria: available

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Jan 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2022
First posted
May 2, 2022
StartEst.
Jan 2024
Primary completionEst.
Jan 2025
CompletionEst.
Jan 2025
Last update
Apr 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05355207
Lead sponsor
Trellis Bioscience LLC
Responsible party
Sponsor
First posted
May 2, 2022
Start date
Jan 2024 (estimated)
Primary completion
Jan 2025 (estimated)
Completion
Jan 2025 (estimated)
Last update
Apr 12, 2023

Study contacts

Anton (Tony) Leighton, MD
Contact
Clinicalstudies@trellisbio.com
650-838-1400
Adriane Kisch-Hancock
Contact
akisch-hancock@trellisbio.com
650-838-1400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRL1068

Start the discussion